MET mutation

We report a 59-year-old female non-smoker with stage IV EGFR Leu858Arg-mutated lung adenocarcinoma who sequentially received first-line osimertinib (~9 months), second-line osimertinib plus savolitinib for MET amplification (~20 months), third-line platinum-based chemotherapy with local ablative therapy for oligo-progression, and fourth-line docetaxel. This case illustrates that an acquired BRAF fusion may emerge as a potentially targetable bypass alteration in EGFR-mutated MET-amplified NSCLC after progression on combined EGFR-MET inhibition and that the combination of a first-generation EGFR-TKI and a MEK inhibitor can be associated with prolonged systemic disease control. The findings are hypothesis-generating and support the value of CGP at sequential progression points to guide mechanism-based therapy in oncogene-driven NSCLC.

P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028

This case underscores dynamic clonal evolution in advanced NSCLC: the initial L747S/L858R clone showed Osimertinib sensitivity, while subsequent resistance revealed a distinct profile (distinct TP53 mutation, MET amplification, high PD-L1/TMB) that explained the durable response to Pembrolizumab. These findings provide crucial evidence for sequential therapy strategies in compound EGFR mutations. Our findings also highlight the utility of Next Generation Sequencing (NGS) in identifying targetable resistance mechanisms, enabling prolonged survival in patients with compound EGFR mutations and offering valuable insights for clinical decision-making.

They showed high success rates (98%) for FFPE tissue, whereas liquid biopsy tests had lower rates (37.5% in 2022, 63% in 2024), primarily due to low allelic fractions and intronic deletions. This study highlights the importance of analyzing both DNA and RNA, urging improvements in sensitivity, coverage and bioinformatics.

These findings highlight non-tobacco environmental exposures in young lung cancer and support further investigation of dietary patterns and hormonal factors in mutation-specific disease pathways.

While vebreltinib appears clinically advantageous over crizotinib for METex14-mutated NSCLC, the therapeutic benefits did not reach statistical significance in this study. The observed differential response patterns and resistance mechanisms suggest distinct biological behaviors to type Ia and Ib MET TKIs that warrant further investigation. These findings underscore the need for larger prospective studies to validate the potential superiority of vebreltinib and to better characterize the molecular determinants in NSCLC.

Prior anti-EGFR therapy and resistance alterations detected by baseline ctDNA profiling are associated with reduced efficacy of PER + TRA in HER2-amplified mCRC. Integrating treatment history with baseline ctDNA profiling might enable improved patient selection for dual HER2-targeted therapy.

This study enriches the current volume of evidence on histopathologic, genetic, immunologic correlates of PD-L1 expression and, to our knowledge, is the first comprehensive analysis of arm-level alterations. Further studies are warranted to validate these finding and to determine their associations with clinical outcomes.

MRI-based radiomics demonstrates significant potential in predicting key pathological features and long-term survival outcomes in rectal cancer patients. Integrating multimodal imaging data and clinical information, along with automated segmentation techniques, could further enhance model accuracy and clinical utility.

MET alterations occur predominantly in the elderly, males, and smokers. MET-Ex14 shows driver-dependent characteristics with clear MET-TKI benefit. MET-Amp presents the most aggressive phenotype. MET IHC-Pos predominates (> 80%) with heterogeneity; the 2 + /3 + may benefit from MET-TKI. These findings inform subtype-based management of MET-altered NSCLC in southeastern China.

Met-ctDNA is a versatile, non-invasive biomarker with diagnostic, prognostic, and predictive value in NSCLC. Standardization of methodologies and validation in large-scale prospective trials are essential to enable its integration into routine clinical practice.

IDH1 status showed significant interactions with adjuvant chemotherapy cycles (P=0.007) and MGMT methylation status (P=0.040), respectively. In conclusion, IDH1 mutation is an independent predictor of good treatment response and improved prognosis in patients with HGGs receiving concurrent chemoradiotherapy, and the validated nomogram can serve as a practical tool for individualized clinical decision-making.